ArticleCureus2026
Supergiant Facial Basal Cell Carcinoma With Orbital Involvement: A Preventable Consequence of Delayed Diagnosis and Limited Access to Care.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Supergiant basal cell carcinoma is an exceptionally rare presentation of an otherwise highly curable malignancy and is most often associated with prolonged neglect and limited access to care. We report a case of a 94-year-old man with a long-standing infiltrative facial lesion extending from the right preauricular and temporal region to the nasal sidewall and lower eyelid, associated with ectropion. Dermoscopy revealed blue-gray globules and pigmented ovoid nests, along with white structureless areas and a milky-red background. Biopsy confirmed pigmented basal cell carcinoma. Given advanced local invasion, frailty, and the unavailability of hedgehog pathway inhibitors in the public healthcare system, curative treatment was not feasible, and palliative radiotherapy was initiated. The patient deteriorated and died shortly thereafter; no evidence of metastatic disease was identified, and death was not attributed to basal cell carcinoma. This case highlights how delays in diagnosis and limited access to modern systemic therapies can transform a typically low-mortality cancer into a source of significant morbidity. Strengthening early detection strategies and improving access to guideline-based treatments remain critical to preventing such outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.